WO2006118246A1 - 経皮吸収促進剤 - Google Patents
経皮吸収促進剤 Download PDFInfo
- Publication number
- WO2006118246A1 WO2006118246A1 PCT/JP2006/308975 JP2006308975W WO2006118246A1 WO 2006118246 A1 WO2006118246 A1 WO 2006118246A1 JP 2006308975 W JP2006308975 W JP 2006308975W WO 2006118246 A1 WO2006118246 A1 WO 2006118246A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- liquid crystal
- lyotropic liquid
- weight
- absorption enhancer
- retinoic acid
- Prior art date
Links
- 239000003655 absorption accelerator Substances 0.000 title abstract 4
- 239000004976 Lyotropic liquid crystal Substances 0.000 claims abstract description 100
- 238000010521 absorption reaction Methods 0.000 claims abstract description 66
- 239000004480 active ingredient Substances 0.000 claims abstract description 34
- 239000000126 substance Substances 0.000 claims abstract description 20
- 229920000642 polymer Polymers 0.000 claims abstract description 5
- 239000003623 enhancer Substances 0.000 claims description 43
- 239000000203 mixture Substances 0.000 claims description 42
- -1 polyoxyethylene Polymers 0.000 claims description 40
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 38
- 239000010419 fine particle Substances 0.000 claims description 33
- 239000004094 surface-active agent Substances 0.000 claims description 19
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 14
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 14
- 239000000194 fatty acid Substances 0.000 claims description 14
- 229930195729 fatty acid Natural products 0.000 claims description 14
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 claims description 14
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 11
- 239000002736 nonionic surfactant Substances 0.000 claims description 11
- 239000003921 oil Substances 0.000 claims description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims description 10
- 150000005846 sugar alcohols Polymers 0.000 claims description 10
- 235000011187 glycerol Nutrition 0.000 claims description 7
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 claims description 6
- 229940032094 squalane Drugs 0.000 claims description 6
- 239000004359 castor oil Substances 0.000 claims description 5
- 235000019438 castor oil Nutrition 0.000 claims description 5
- 235000012000 cholesterol Nutrition 0.000 claims description 5
- 239000004064 cosurfactant Substances 0.000 claims description 5
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 5
- 108090000623 proteins and genes Proteins 0.000 claims description 5
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 claims description 4
- 229920001214 Polysorbate 60 Polymers 0.000 claims description 4
- 239000000787 lecithin Substances 0.000 claims description 4
- 235000010445 lecithin Nutrition 0.000 claims description 4
- 229940067606 lecithin Drugs 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- 102000004169 proteins and genes Human genes 0.000 claims description 4
- 108091034117 Oligonucleotide Proteins 0.000 claims description 3
- 150000005215 alkyl ethers Chemical class 0.000 claims description 3
- 150000002894 organic compounds Chemical class 0.000 claims description 3
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 3
- 229940100640 transdermal system Drugs 0.000 claims 1
- 239000003814 drug Substances 0.000 abstract description 6
- 239000002537 cosmetic Substances 0.000 abstract description 5
- SHGAZHPCJJPHSC-YCNIQYBTSA-N all-trans-retinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C SHGAZHPCJJPHSC-YCNIQYBTSA-N 0.000 description 59
- 229930002330 retinoic acid Natural products 0.000 description 58
- 229960001727 tretinoin Drugs 0.000 description 58
- 239000004973 liquid crystal related substance Substances 0.000 description 42
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 38
- 210000003491 skin Anatomy 0.000 description 35
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 24
- 239000008280 blood Substances 0.000 description 20
- 210000004369 blood Anatomy 0.000 description 20
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 19
- 102000004877 Insulin Human genes 0.000 description 19
- 108090001061 Insulin Proteins 0.000 description 19
- 229940125396 insulin Drugs 0.000 description 19
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 18
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 15
- 239000001095 magnesium carbonate Substances 0.000 description 15
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 15
- VYGQUTWHTHXGQB-FFHKNEKCSA-N Retinol Palmitate Chemical compound CCCCCCCCCCCCCCCC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C VYGQUTWHTHXGQB-FFHKNEKCSA-N 0.000 description 12
- 229910000019 calcium carbonate Inorganic materials 0.000 description 12
- 239000002105 nanoparticle Substances 0.000 description 12
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 11
- 210000002615 epidermis Anatomy 0.000 description 11
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 11
- 238000002156 mixing Methods 0.000 description 11
- 102400001369 Heparin-binding EGF-like growth factor Human genes 0.000 description 10
- 101800001649 Heparin-binding EGF-like growth factor Proteins 0.000 description 10
- 235000005152 nicotinamide Nutrition 0.000 description 10
- 239000011570 nicotinamide Substances 0.000 description 10
- 230000001737 promoting effect Effects 0.000 description 10
- 102000019197 Superoxide Dismutase Human genes 0.000 description 9
- 108010012715 Superoxide dismutase Proteins 0.000 description 9
- 239000006185 dispersion Substances 0.000 description 9
- 229960003966 nicotinamide Drugs 0.000 description 9
- 235000019198 oils Nutrition 0.000 description 9
- 229920002307 Dextran Polymers 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004519 manufacturing process Methods 0.000 description 8
- 229940099259 vaseline Drugs 0.000 description 8
- 230000002535 lyotropic effect Effects 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 230000036560 skin regeneration Effects 0.000 description 7
- 159000000000 sodium salts Chemical class 0.000 description 7
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000007864 aqueous solution Substances 0.000 description 6
- 239000012153 distilled water Substances 0.000 description 6
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 229940108325 retinyl palmitate Drugs 0.000 description 6
- 235000019172 retinyl palmitate Nutrition 0.000 description 6
- 239000011769 retinyl palmitate Substances 0.000 description 6
- FPIPGXGPPPQFEQ-OVSJKPMPSA-N all-trans-retinol Chemical compound OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-OVSJKPMPSA-N 0.000 description 5
- 230000015572 biosynthetic process Effects 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000006210 lotion Substances 0.000 description 5
- 239000000693 micelle Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 4
- 210000002510 keratinocyte Anatomy 0.000 description 4
- 150000002632 lipids Chemical class 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 239000002245 particle Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000010186 staining Methods 0.000 description 4
- 210000000434 stratum corneum Anatomy 0.000 description 4
- FPIPGXGPPPQFEQ-UHFFFAOYSA-N 13-cis retinol Natural products OCC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C FPIPGXGPPPQFEQ-UHFFFAOYSA-N 0.000 description 3
- 239000002202 Polyethylene glycol Substances 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 229920002125 Sokalan® Polymers 0.000 description 3
- 239000000470 constituent Substances 0.000 description 3
- 230000004069 differentiation Effects 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000010408 film Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 229920001223 polyethylene glycol Polymers 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 229960003471 retinol Drugs 0.000 description 3
- 235000020944 retinol Nutrition 0.000 description 3
- 239000011607 retinol Substances 0.000 description 3
- 231100000245 skin permeability Toxicity 0.000 description 3
- 230000008719 thickening Effects 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 2
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 2
- JLPULHDHAOZNQI-ZTIMHPMXSA-N 1-hexadecanoyl-2-(9Z,12Z-octadecadienoyl)-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCC\C=C/C\C=C/CCCCC JLPULHDHAOZNQI-ZTIMHPMXSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QHNVWXUULMZJKD-UHFFFAOYSA-N 3,4-didehydroretinal Chemical compound O=CC=C(C)C=CC=C(C)C=CC1=C(C)C=CCC1(C)C QHNVWXUULMZJKD-UHFFFAOYSA-N 0.000 description 2
- 241001143500 Aceraceae Species 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- 241000700199 Cavia porcellus Species 0.000 description 2
- 108020004414 DNA Proteins 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000004264 Petrolatum Substances 0.000 description 2
- 241000700157 Rattus norvegicus Species 0.000 description 2
- BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- FMRLDPWIRHBCCC-UHFFFAOYSA-L Zinc carbonate Chemical compound [Zn+2].[O-]C([O-])=O FMRLDPWIRHBCCC-UHFFFAOYSA-L 0.000 description 2
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- SYESMXTWOAQFET-YCNIQYBTSA-N all-trans-3,4-didehydroretinoic acid Chemical compound OC(=O)\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)C=CCC1(C)C SYESMXTWOAQFET-YCNIQYBTSA-N 0.000 description 2
- BJRNKVDFDLYUGJ-ZIQFBCGOSA-N alpha-Arbutin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-ZIQFBCGOSA-N 0.000 description 2
- 150000003863 ammonium salts Chemical class 0.000 description 2
- 230000002421 anti-septic effect Effects 0.000 description 2
- 239000003963 antioxidant agent Substances 0.000 description 2
- 229960000271 arbutin Drugs 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 229910000389 calcium phosphate Inorganic materials 0.000 description 2
- 235000011010 calcium phosphates Nutrition 0.000 description 2
- 239000003093 cationic surfactant Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 230000000052 comparative effect Effects 0.000 description 2
- SZXQTJUDPRGNJN-UHFFFAOYSA-N dipropylene glycol Chemical compound OCCCOCCCO SZXQTJUDPRGNJN-UHFFFAOYSA-N 0.000 description 2
- 239000000975 dye Substances 0.000 description 2
- 150000004665 fatty acids Chemical class 0.000 description 2
- 239000003349 gelling agent Substances 0.000 description 2
- 230000002209 hydrophobic effect Effects 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940094443 oxytocics prostaglandins Drugs 0.000 description 2
- BJRNKVDFDLYUGJ-UHFFFAOYSA-N p-hydroxyphenyl beta-D-alloside Natural products OC1C(O)C(O)C(CO)OC1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-UHFFFAOYSA-N 0.000 description 2
- 235000019271 petrolatum Nutrition 0.000 description 2
- 229940066842 petrolatum Drugs 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 229940083466 soybean lecithin Drugs 0.000 description 2
- 229940031439 squalene Drugs 0.000 description 2
- TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 2
- 238000010254 subcutaneous injection Methods 0.000 description 2
- 239000007929 subcutaneous injection Substances 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000010409 thin film Substances 0.000 description 2
- 230000037317 transdermal delivery Effects 0.000 description 2
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- 239000011667 zinc carbonate Substances 0.000 description 2
- 235000004416 zinc carbonate Nutrition 0.000 description 2
- 229910000010 zinc carbonate Inorganic materials 0.000 description 2
- DNIAPMSPPWPWGF-VKHMYHEASA-N (+)-propylene glycol Chemical compound C[C@H](O)CO DNIAPMSPPWPWGF-VKHMYHEASA-N 0.000 description 1
- JQWAHKMIYCERGA-UHFFFAOYSA-N (2-nonanoyloxy-3-octadeca-9,12-dienoyloxypropoxy)-[2-(trimethylazaniumyl)ethyl]phosphinate Chemical compound CCCCCCCCC(=O)OC(COP([O-])(=O)CC[N+](C)(C)C)COC(=O)CCCCCCCC=CCC=CCCCCC JQWAHKMIYCERGA-UHFFFAOYSA-N 0.000 description 1
- ORTVZLZNOYNASJ-UPHRSURJSA-N (z)-but-2-ene-1,4-diol Chemical compound OC\C=C/CO ORTVZLZNOYNASJ-UPHRSURJSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- YPFDHNVEDLHUCE-UHFFFAOYSA-N 1,3-propanediol Substances OCCCO YPFDHNVEDLHUCE-UHFFFAOYSA-N 0.000 description 1
- 229940035437 1,3-propanediol Drugs 0.000 description 1
- PZNPLUBHRSSFHT-RRHRGVEJSA-N 1-hexadecanoyl-2-octadecanoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCCCC(=O)O[C@@H](COP([O-])(=O)OCC[N+](C)(C)C)COC(=O)CCCCCCCCCCCCCCC PZNPLUBHRSSFHT-RRHRGVEJSA-N 0.000 description 1
- JCTXKRPTIMZBJT-UHFFFAOYSA-N 2,2,4-trimethylpentane-1,3-diol Chemical compound CC(C)C(O)C(C)(C)CO JCTXKRPTIMZBJT-UHFFFAOYSA-N 0.000 description 1
- ZLBTVOAZVODUBE-UHFFFAOYSA-N 2,2-bis(hydroxymethyl)propane-1,3-diol 2-(2-hydroxyethoxy)ethanol prop-1-ene Chemical compound CC=C.OCCOCCO.OCC(CO)(CO)CO ZLBTVOAZVODUBE-UHFFFAOYSA-N 0.000 description 1
- QTYBXUYQRXYHKH-UHFFFAOYSA-N 2-methylpropane-1,3-diol Chemical compound OCC([CH2])CO QTYBXUYQRXYHKH-UHFFFAOYSA-N 0.000 description 1
- SXFJDZNJHVPHPH-UHFFFAOYSA-N 3-methylpentane-1,5-diol Chemical compound OCCC(C)CCO SXFJDZNJHVPHPH-UHFFFAOYSA-N 0.000 description 1
- CYDQOEWLBCCFJZ-UHFFFAOYSA-N 4-(4-fluorophenyl)oxane-4-carboxylic acid Chemical compound C=1C=C(F)C=CC=1C1(C(=O)O)CCOCC1 CYDQOEWLBCCFJZ-UHFFFAOYSA-N 0.000 description 1
- HIQIXEFWDLTDED-UHFFFAOYSA-N 4-hydroxy-1-piperidin-4-ylpyrrolidin-2-one Chemical compound O=C1CC(O)CN1C1CCNCC1 HIQIXEFWDLTDED-UHFFFAOYSA-N 0.000 description 1
- ODHCTXKNWHHXJC-VKHMYHEASA-M 5-oxo-L-prolinate Chemical compound [O-]C(=O)[C@@H]1CCC(=O)N1 ODHCTXKNWHHXJC-VKHMYHEASA-M 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- IAYPIBMASNFSPL-UHFFFAOYSA-N Ethylene oxide Chemical compound C1CO1 IAYPIBMASNFSPL-UHFFFAOYSA-N 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- CWLQUGTUXBXTLF-UHFFFAOYSA-N N-methyl-L-proline monohydrate Natural products CN1CCCC1C(O)=O CWLQUGTUXBXTLF-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- ALQSHHUCVQOPAS-UHFFFAOYSA-N Pentane-1,5-diol Chemical compound OCCCCCO ALQSHHUCVQOPAS-UHFFFAOYSA-N 0.000 description 1
- 206010051246 Photodermatosis Diseases 0.000 description 1
- 229920001030 Polyethylene Glycol 4000 Polymers 0.000 description 1
- DBMJMQXJHONAFJ-UHFFFAOYSA-M Sodium laurylsulphate Chemical compound [Na+].CCCCCCCCCCCCOS([O-])(=O)=O DBMJMQXJHONAFJ-UHFFFAOYSA-M 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000037374 absorbed through the skin Effects 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 150000003973 alkyl amines Chemical class 0.000 description 1
- 125000005211 alkyl trimethyl ammonium group Chemical group 0.000 description 1
- 229930002945 all-trans-retinaldehyde Natural products 0.000 description 1
- 229940033280 alpha-arbutin Drugs 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000003796 beauty Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- FFBHFFJDDLITSX-UHFFFAOYSA-N benzyl N-[2-hydroxy-4-(3-oxomorpholin-4-yl)phenyl]carbamate Chemical compound OC1=C(NC(=O)OCC2=CC=CC=C2)C=CC(=C1)N1CCOCC1=O FFBHFFJDDLITSX-UHFFFAOYSA-N 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 235000013877 carbamide Nutrition 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- RJECHNNFRHZQKU-RMUVNZEASA-N cholesteryl oleate Chemical compound C([C@@H]12)C[C@]3(C)[C@@H]([C@H](C)CCCC(C)C)CC[C@H]3[C@@H]1CC=C1[C@]2(C)CC[C@H](OC(=O)CCCCCCC\C=C/CCCCCCCC)C1 RJECHNNFRHZQKU-RMUVNZEASA-N 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- 125000004122 cyclic group Chemical group 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 description 1
- 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
- 229940113120 dipropylene glycol Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- LQZZUXJYWNFBMV-UHFFFAOYSA-N dodecan-1-ol Chemical compound CCCCCCCCCCCCO LQZZUXJYWNFBMV-UHFFFAOYSA-N 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000000122 growth hormone Substances 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 125000004836 hexamethylene group Chemical group [H]C([H])([*:2])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[*:1] 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 125000001165 hydrophobic group Chemical group 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 230000007794 irritation Effects 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 229960000448 lactic acid Drugs 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- GVALZJMUIHGIMD-UHFFFAOYSA-H magnesium phosphate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O GVALZJMUIHGIMD-UHFFFAOYSA-H 0.000 description 1
- 239000004137 magnesium phosphate Substances 0.000 description 1
- 229910000157 magnesium phosphate Inorganic materials 0.000 description 1
- 229960002261 magnesium phosphate Drugs 0.000 description 1
- 235000010994 magnesium phosphates Nutrition 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 229910021645 metal ion Inorganic materials 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- SLCVBVWXLSEKPL-UHFFFAOYSA-N neopentyl glycol Chemical compound OCC(C)(C)CO SLCVBVWXLSEKPL-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- WWZKQHOCKIZLMA-UHFFFAOYSA-M octanoate Chemical compound CCCCCCCC([O-])=O WWZKQHOCKIZLMA-UHFFFAOYSA-M 0.000 description 1
- 239000003883 ointment base Substances 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- WCVRQHFDJLLWFE-UHFFFAOYSA-N pentane-1,2-diol Chemical compound CCCC(O)CO WCVRQHFDJLLWFE-UHFFFAOYSA-N 0.000 description 1
- 230000000737 periodic effect Effects 0.000 description 1
- 239000012466 permeate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229920001515 polyalkylene glycol Polymers 0.000 description 1
- 229920001083 polybutene Polymers 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 229920000166 polytrimethylene carbonate Polymers 0.000 description 1
- BITYAPCSNKJESK-UHFFFAOYSA-N potassiosodium Chemical compound [Na].[K] BITYAPCSNKJESK-UHFFFAOYSA-N 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- FOWDZVNRQHPXDO-UHFFFAOYSA-N propyl hydrogen carbonate Chemical compound CCCOC(O)=O FOWDZVNRQHPXDO-UHFFFAOYSA-N 0.000 description 1
- 229940071139 pyrrolidone carboxylate Drugs 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-OVSJKPMPSA-N retinal group Chemical group C\C(=C/C=O)\C=C\C=C(\C=C\C1=C(CCCC1(C)C)C)/C NCYCYZXNIZJOKI-OVSJKPMPSA-N 0.000 description 1
- 238000005464 sample preparation method Methods 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 239000000344 soap Substances 0.000 description 1
- 239000001540 sodium lactate Substances 0.000 description 1
- 229940005581 sodium lactate Drugs 0.000 description 1
- 235000011088 sodium lactate Nutrition 0.000 description 1
- 235000019333 sodium laurylsulphate Nutrition 0.000 description 1
- 229940045920 sodium pyrrolidone carboxylate Drugs 0.000 description 1
- HYRLWUFWDYFEES-UHFFFAOYSA-M sodium;2-oxopyrrolidine-1-carboxylate Chemical compound [Na+].[O-]C(=O)N1CCCC1=O HYRLWUFWDYFEES-UHFFFAOYSA-M 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 239000008347 soybean phospholipid Substances 0.000 description 1
- 230000006641 stabilisation Effects 0.000 description 1
- 238000011105 stabilization Methods 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003871 sulfonates Chemical class 0.000 description 1
- 230000002459 sustained effect Effects 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 230000000699 topical effect Effects 0.000 description 1
- 230000007704 transition Effects 0.000 description 1
- 238000002834 transmittance Methods 0.000 description 1
- ZIBGPFATKBEMQZ-UHFFFAOYSA-N triethylene glycol Chemical compound OCCOCCOCCO ZIBGPFATKBEMQZ-UHFFFAOYSA-N 0.000 description 1
- VLPFTAMPNXLGLX-UHFFFAOYSA-N trioctanoin Chemical compound CCCCCCCC(=O)OCC(OC(=O)CCCCCCC)COC(=O)CCCCCCC VLPFTAMPNXLGLX-UHFFFAOYSA-N 0.000 description 1
- 229940045136 urea Drugs 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 235000015112 vegetable and seed oil Nutrition 0.000 description 1
- 239000008158 vegetable oil Substances 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 239000010497 wheat germ oil Substances 0.000 description 1
- LRXTYHSAJDENHV-UHFFFAOYSA-H zinc phosphate Chemical compound [Zn+2].[Zn+2].[Zn+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O LRXTYHSAJDENHV-UHFFFAOYSA-H 0.000 description 1
- 229910000165 zinc phosphate Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
- A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
- A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
- A61K31/203—Retinoic acids ; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Liposomes
- A61K9/1274—Non-vesicle bilayer structures, e.g. liquid crystals, tubules, cubic phases, cochleates; Sponge phases
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
Definitions
- the present invention relates to a percutaneous absorption enhancer for percutaneously absorbing various active ingredients.
- Transdermal administration is an excellent administration method because it is simpler than oral administration and administration by injection and has advantages such as sustained efficacy and reduced side effects.
- the active ingredient in order for the active ingredient to penetrate into the body by transdermal administration, the active ingredient must permeate the skin that constitutes the primary barrier of the living body. The amount absorbed into the bloodstream) is inherently low.
- the present inventors have energetically conducted research and development for percutaneously absorbing an active ingredient, and as a result, promote differentiation and proliferation of keratinocytes (keratinocytes).
- keratinocytes keratinocytes
- retinoic acid which has the effect of promoting skin regeneration
- nanometer-order capsules nanoparticles
- transdermal absorption enhancer is added. It has been found that retinoic acid can be transdermally absorbed efficiently and slowly (Non-Patent Document 1 and Non-Patent Document 2).
- Non-Patent Document 1 New nanotechnology for transdermal delivery, Yoko Yamaguchi, Bio Bencher, IV, No. 6, pp. 62–64, 2004
- J j3 ⁇ 42 Y. Yamaguchi, T. Nagasawa, N. Nakamura, M. Takekenaga, M. izogucni, S. Kawai, Y. Mizushima, R. Igarashi, Successlul treatment of photo-damaged skin of na no-scale atRA particles using a novel transdermal delivery, 104, 29—40, 2005 Disclosure of the Invention
- an object of the present invention is to provide a transdermal absorption enhancer for transdermally absorbing various active ingredients.
- transdermal absorption enhancer of the present invention made based on the above findings is characterized in that, as described in claim 1, lyotropic liquid crystal is an active ingredient.
- the transdermal absorption enhancer according to claim 2 is the transdermal absorption enhancer according to claim 1, wherein the lyotropic liquid crystal contains 5% to 80% by weight of a surfactant and 5% to 80% by weight of water. It is what is included.
- the transdermal absorption enhancer according to claim 3 is characterized in that, in the transdermal absorption enhancer according to claim 2, the surfactant is a nonionic surfactant and Z or lecithin.
- the percutaneous absorption enhancer according to claim 4 is the transdermal absorption enhancer according to claim 3, wherein the nonionic surfactant is polyoxyethylene alkyl ether, polyoxyethylene sorbitan fatty acid ester, polyoxyethylene curing agent.
- the castor oil power is at least one selected.
- the percutaneous absorption enhancer according to claim 5 is characterized in that, in the percutaneous absorption enhancer according to claim 2, the lyotropic liquid crystal further contains 1% by weight to 80% by weight of oil.
- the percutaneous absorption enhancer according to claim 6 is characterized in that in the percutaneous absorption enhancer according to claim 5, the oil is squalane.
- the transdermal absorption enhancer according to claim 7 is characterized in that, in the transdermal absorption enhancer according to claim 2, the lyotropic liquid crystal further contains 1% by weight to 55% by weight of a polyhydric alcohol.
- the percutaneous absorption enhancer according to claim 8 is the transdermal absorption enhancer according to claim 7, characterized in that the polyhydric alcohol is glycerin.
- the transdermal absorption enhancer according to claim 9 is the transdermal absorption enhancer according to claim 2, wherein the lyotropic liquid crystal further contains 0.01 to 10% by weight of a cosurfactant. It is characterized by.
- the percutaneous absorption enhancer according to claim 10 is characterized in that the cosurfactant is cholesterol as compared with the percutaneous absorption enhancer according to claim 9.
- the percutaneous absorption composition of the present invention is characterized in that, as described in claim 11, an active ingredient is blended in the lyotropic liquid crystal.
- the percutaneous absorption composition according to claim 12 is the percutaneous absorption composition according to claim 11, wherein the active ingredient is at least one selected from organic compounds, peptides, proteins, oligonucleotides, DNA, and RNA. It is characterized by being.
- the percutaneous absorption composition according to claim 13 is characterized in that, in the percutaneous absorption composition according to claim 11, the active ingredient is a polymer substance having a molecular weight of 1000 or more or a water-soluble substance. .
- the percutaneous absorption composition according to claim 14 is blended in the percutaneous absorption composition according to claim 11 in a form in which the active ingredient is encapsulated inside the divalent metal inorganic acid salt fine particles. It is characterized by that.
- the percutaneous absorption composition according to claim 15 is the transdermal absorption composition according to claim 11, wherein the active ingredient is blended in an amount of 0.01% to 50% with respect to the lyotropic liquid crystal. It is characterized by that.
- Rioto has been used as a base material for topical medicines and cosmetics.
- a novel transdermal absorption enhancer for use in oral pick liquid crystals is provided, and the transdermal absorption enhancer of the present invention can absorb various active ingredients transdermally.
- FIG. 1 is a graph showing changes in blood retinoic acid concentration in Example 1.
- FIG. 2 is a graph showing changes in HB-EGF production when each of the four types of samples in Example 2 is applied.
- FIG. 3 is a graph showing changes in the amount of HB-EGF produced when each of the four types of samples in Example 3 was applied and the amount of HB-EGF produced in an uncoated skin.
- FIG. 4 A cross-sectional photograph of the skin when each of the five samples in Example 4 was applied, and a cross-sectional photograph of the skin when nothing was applied.
- FIG. 5 is a graph showing changes in blood insulin concentration in Example 5.
- FIG. 6 is a graph showing the change with time of the ratio of niacinamide in whole blood with respect to the dose in Example 6.
- FIG. 7 is a graph showing changes over time in the residual ratio of retinoic acid in five types of samples in Example 7.
- FIG. 8 is a graph showing changes over time in the residual ratio of retinol palmitate in four types of samples in Example 8.
- FIG. 9 is a cross-sectional photograph of the skin coated with lyotropic liquid crystal containing SOD in Example 9.
- FIG. 10 is a cross-sectional photograph of the skin coated with a dispersion obtained by dispersing SOD in water.
- FIG. 11 A cross-sectional photograph of the skin where only water is applied.
- FIG. 12 is a cross-sectional photograph of the skin when each of the six types of samples in Example 10 is applied.
- FIG. 13 is a fluorescence cross-sectional photograph of skin coated with lyotropic liquid crystal containing oligo DNA fluorescently labeled with FITC in Example 11.
- FIG. 14 is a fluorescent cross-sectional photograph of skin coated with a dispersion of oligo DNA fluorescently labeled with FITC in water.
- FIG.15 Formulated with FITC fluorescently labeled dextran (molecular weight 4000) in Example 12 It is the fluorescence cross-section photograph of the skin which applied lyotropic liquid crystal.
- FIG. 16 Fluorescence cross-sectional photograph of skin coated with lyotropic liquid crystal conjugated with FITC fluorescently labeled dextran (molecular weight 70000) in Example 13 and FITC fluorescently labeled dextran (same as above) dispersed in water It is the fluorescence cross-sectional photograph of the skin which apply
- the transdermal absorption enhancer of the present invention comprises lyotropic liquid crystal as an active ingredient.
- the lyotropic liquid crystal in the present invention is a coexisting system of a surfactant (an amphiphilic molecule having a hydrophilic part and a hydrophobic (lipophilic) part in the molecule) and water. It means a liquid crystal state (a state in which the molecular arrangement has a certain fluidity like a liquid while maintaining a certain regularity like a crystal) depending on the mixing ratio and temperature of the two.
- lyotropic liquid crystal water is added to a solid-state surfactant having a crystalline structure in which hydrophobic portions (hydrophobic groups such as alkyl groups) face each other in a predetermined temperature range.
- the part loses regularity due to thermal motion and becomes a liquid state, but this time the hydrophilic part acts by hydrogen bonding and maintains a long period to take an associative structure (hexagonal structure, lamellar structure, etc.) (If necessary, see “Toshiyuki Suzuki, Liquid Crystal, Vol. 2, 194–201, 1998”).
- Surfactant that is a constituent component of lyotropic liquid crystal forms a liquid crystal state (especially, a periodic structure with a surface spacing of ⁇ ! To 800 nm is desirable) depending on the mixing ratio and temperature with water in a coexisting system with water
- It can be any non-ionic type, ionic type, cationic type or amphoteric type surfactant, as long as it can be used.
- Naturally derived surfactants such as lecithin (eg, egg yolk lecithin and soybean lecithin) and saponin may be used.
- a single surfactant may be used alone, or a plurality of surfactants may be mixed and used.
- Nonionic surfactants include polyoxyethylene alkyl ether, polyoxyethylene alkyl phenol ether, alkyl darcoside, polyoxyethylene fatty acid ester, sucrose fatty acid ester, sorbitan fatty acid ester, polyoxyethylene sorbitan fatty acid ester. Fatty acid alkanolamide, polyoxyethylene hydrogenated castor oil, and the like.
- soap fatty acid sodium Potassium salt
- alkylbenzene sulfonate sodium salt
- higher alcohol sulfate sodium salt
- polyoxyethylene alkyl ether sulfate sodium salt
- ⁇ -sulfo fatty acid ester ⁇
- examples include lefine sulfonates (such as sodium salts), monoalkyl phosphate salts (such as sodium salts), and alkane sulfonates (such as sodium salts).
- Cationic surfactants include alkyltrimethyl ammonium salts (such as chloride), dialkyldimethyl ammonium salts (such as chloride), alkyldimethylbenzyl ammonium salts (such as chloride), amine salts (such as chloride). Acetate, hydrochloride, etc.).
- amphoteric surfactants include alkylamino fatty acid salts (such as sodium salts), alkylbetaines, and alkylamine oxides.
- the proportion of the surfactant in the lyotropic liquid crystal is preferably 5 to 80% by weight, more preferably 7 to 70% by weight, and even more preferably 10 to 65% by weight.
- Surfactant HLB value is preferably 8 or more, more preferably 10 or more, and even more preferably 12 or more
- Distilled water or the like can be used as water as a constituent component of the lyotropic liquid crystal.
- Water may contain an organic solvent compatible with water, such as ethanol or isopropanol.
- the proportion of water in the lyotropic liquid crystal is preferably 5% to 80% by weight, more preferably 10% to 60% by weight, and even more preferably 13% to 50% by weight.
- the lyotropic liquid crystal may contain an oil component in addition to the surfactant and water.
- oil By containing oil, the liquid crystal structure approximates to the lamellar structure formed by intercellular lipids in the stratum corneum, making it easier to cause phase transition of intercellular lipid structures when applied to the skin surface. Excellent transdermal absorption for active ingredients.
- Oils include wheat germ oil, corn oil, castor oil, castor oil, soybean oil and other vegetable oils, silicone oil, isopropyl myristate glyceryl trioctanoate, diethylene glycol monopropylene pentaerythritol ether and pentaerythrityl tetra Examples include ester oils such as octanoate, squalane, squalene, liquid paraffin, and polybutene. A single oil component may be used alone, or a plurality of types may be used in combination.
- the proportion of oil in the lyotropic liquid crystal is preferably 1 to 80% by weight, more preferably 5 to 70% by weight, and even more preferably 10 to 65% by weight.
- the lyotropic liquid crystal may contain a polyhydric alcohol.
- polyhydric alcohol such as polyethylene glycol and polyalkylene glycol, glycerin, propylene glycol, 1,3 propanediol, 2-butene 1,4-diol, pentane 1,5 diol, 2,2 dimethylpropane 1 , 3 diol, 3-methylpentane 1,5 diol, pentane 1,2 diol, 2, 2, 4 trimethylpentane 1,3 diol, 2 methylpropane 1,3 diol, hexylene glycol, 1,3 butylene glycol , Dipropylene glycol, polyethylene glycol, triethylene glycol and the like.
- a single polyhydric alcohol may be used alone, or a plurality of types may be mixed and used.
- the proportion of polyhydric alcohol in the lyotropic liquid crystal is preferably 1% to 55% by weight, more preferably 3% to 52% by weight, and further preferably 5% to 50% by weight.
- the lyotropic liquid crystal may contain cholesterol or the like as an auxiliary surfactant.
- the auxiliary surfactant By including the auxiliary surfactant, it is possible to reduce the curvature of the interface film even when a wide variety of surfactants are used, thereby facilitating the formation and stabilization of the liquid crystal structure.
- the proportion of the cosurfactant in the lyotropic liquid crystal is preferably 0.01% to 10% by weight.
- the lyotropic liquid crystal can be prepared by mixing a surfactant and water as constituent components at a predetermined ratio at a predetermined temperature. If necessary, the operation may be performed when the components are heated temporarily before or after mixing.
- the transdermal absorption enhancer of the present invention can percutaneously absorb various active ingredients without depending on the physicochemical properties of the active ingredients.
- active ingredient means a substance that can be used as a drug for preventing and treating various diseases and maintaining and improving health and beauty for mammals including humans.
- a high molecular weight substance having a molecular weight of 100000 or more (the upper limit of the molecular weight is not limited, for example, 500,000 to 10
- water-soluble substances such as niacinamide (nicotinic acid amide) (for example, a water-soluble substance has a transmittance (1Z absorbance) in the range of 70% to 100% at a wavelength of 450 nm when dispersed in water) It can be defined as ⁇ inside and no macroscopic separation is observed in appearance observation ''), and so on. It is to allow percutaneous absorption of the ingredients that have been made.
- the transdermal absorption enhancer of the present invention contains lyotropic liquid crystal that has been used as a base material for externally used pharmaceuticals and cosmetics as an active ingredient. Therefore, a transdermal absorption composition can be obtained by adding an active ingredient to lyotropic liquid crystal. be able to.
- the compounding amount of the active ingredient is, for example, 0.01% to 50% by weight with respect to the lyotropic liquid crystal.
- keratinocyte differentiation'proliferation promoting substances include retinal, 3-dehydroretinal, retinoic acid, 3-dehydroretinoic acid, retinoic acid analog, retinol, retinol fatty acid ester, 3-dehydroretinoic acid. Examples include fatty acid esters.
- substances having an inhibitory action on melanin pigment production include ascorbic acid darcoside, arbutin, superoxide dismutase (SOD), and the like.
- substance having an action of promoting the synthesis of intercellular lipids in the stratum corneum include niacinamide. These substances may be blended by uniformly dispersing themselves in lyotropic liquid crystals and incorporating them between phases of the liquid crystal structure, or divalent metal inorganic acid salt fine particles, for example, calcium carbonate having a diameter of 100 nm to 1000 nm.
- Fine particles, magnesium carbonate fine particles, zinc carbonate fine particles, calcium phosphate fine particles, magnesium phosphate fine particles, zinc phosphate fine particles are encapsulated inside (if necessary, refer to the pamphlet of International Publication No. 02Z096396).
- Fine particles (nanoparticles) encapsulating substances may be blended by uniformly dispersing them in lyotropic liquid crystals and incorporating them between phases of the liquid crystal structure.
- divalent metal ions and their counterions on the surface of the lyotropic liquid crystal (interfacial film) and increasing the viscoelasticity of the film, the physicochemical stability of the substances incorporated between the phases is improved. be able to.
- the percutaneous absorption enhancer of the present invention It can also be used as V, if it is applied to the skin surface and then absorbed through the skin by later adding the active ingredient.
- the percutaneous absorption enhancer of the present invention may be directly applied to the skin surface as an external preparation, or may be dispersed in an ointment base, cream base or lotion base and applied to the skin surface. It's good. Needless to say, known ingredients such as preservatives, moisturizers and antioxidants may be appropriately added during formulation.
- Nanoparticles encapsulating retinoic acid (all trans isomers, the same applies hereinafter) as active ingredients with the three prescription powers listed in Table 1 were prepared as follows.
- retinoic acid, ethanol, and 1N aqueous sodium hydroxide solution were added to uniformly dissolve retinoic acid.
- glycerin and trade name: Emulgen 2020G-HA (polyoxyethylene otatilde decyl ester), which is a nonionic surfactant of Kao Corporation were added and stirred for about 10 minutes.
- distilled water was added and stirring was continued for about 10 minutes to obtain mixed micelles of retinoic acid and nonionic surfactant.
- 5M magnesium chloride aqueous solution or 5M calcium chloride aqueous solution was added, and stirring was continued for about 1 hour.
- a 1M sodium carbonate aqueous solution was added and stirred for about 1 hour to obtain nanoparticles in which retinoic acid was encapsulated in a magnesium carbonate thin film or calcium carbonate thin film having a diameter of ⁇ m to 1000 nm.
- a lyotropic liquid crystal (surfactant 28.0 wt%, water 16.0 wt%, oil 25.0 wt%, polyhydric alcohol 31.0 wt%).
- the nanoparticles obtained in step 1 are 0.1% (composition 1), 0.2% (composition 2), in which the amount of retinoic acid is 0.1% (composition 1), 0.2% (composition 2),
- a lyotropic liquid crystal in which the nanoparticles encapsulated with retinoic acid were uniformly dispersed without being decomposed was obtained by blending to a concentration of 0.4% (composition 3).
- the above operations were all performed under light shielding, and the nonionic surfactant was melted at about 60 ° C and the force was used (the same applies hereinafter).
- retinoic acid-encapsulated nanoparticles (retinoic acid-encapsulated calcium carbonate fine particles) were blended so that the liquid crystal of composition 1 and the amount of retinoic acid were the same.
- each of retinoic acid itself was coated with cerium-line containing the same amount of liquid crystal of composition 1 and retinoic acid, and the blood retinoic acid concentration was measured. The results are shown in Figure 1.
- (A) to (E) in Fig. 1 are as follows.
- the blood retinoic acid concentration when lyotropic liquid crystal containing retinoic acid-encapsulated magnesium carbonate fine particles and lyotropic liquid crystal containing retinoic acid-encapsulated calcium carbonate fine particles were applied was subcutaneously compared with that of retinoic acid. Since it was comparable to the blood retinoic acid concentration when injected, it was found that lyotropic liquid crystals have a transdermal absorption promoting effect.
- Vaseline (Mg-atRAZ Vaseline) containing retinoic acid-encapsulated magnesium carbonate fine particles so that the liquid crystal composition of Example 1 and the amount of retinoic acid are the same.
- Example 3 Vaseline (Ca-atRAZ Vaseline) containing calcium carbonate fine particles encapsulated in retinoic acid so as to have the same amount of liquid crystal and retinoic acid in composition 1 of Example 1 [0025]
- Example 3 Vaseline (Ca-atRAZ Vaseline) containing calcium carbonate fine particles encapsulated in retinoic acid so as to have the same amount of liquid crystal and retinoic acid in composition 1 of Example 1 [0025]
- Example 3 Example 3:
- Figure 4 shows a cross-sectional photograph of the skin to which each sample was applied, along with a cross-sectional photograph of the skin to which nothing was applied.
- Fig. 4 thickening of the epidermis was observed when lyotropic liquid crystal containing retinoic acid was applied in various forms and when lyotropic liquid crystal itself was applied.
- Vaseline (Mg-atRAZ Vaseline) containing retinoic acid-encapsulated magnesium carbonate fine particles so that the liquid crystal composition of Example 1 and the amount of retinoic acid were the same.
- a lyotropic liquid crystal containing 0.5%, 1%, and 3% (weight ratio) of insulin (the lyotropic liquid crystal itself was obtained in Step 2 of Example 1) was prepared. Similarly, blood insulin concentration was measured. As a comparative example, 0.2 mg / 200 L of insulin was subcutaneously injected and blood insulin concentration was measured. The results are shown in FIG. In addition, (A) to (D) in FIG. 5 are as follows.
- niacinamide is a water-soluble substance, and therefore it is usually very difficult to absorb through the skin. This was thought to be due to the fact that it was taken into the blood through the capillaries.
- the sample in (B) is composed of retinoic acid-encapsulated calcium carbonate fine particles of composition 1 of Example 1.
- the sample of (D) corresponds to the lyotropic liquid crystal compounded with the retinoic acid-encapsulated magnesium carbonate fine particles having the composition 1 of Example 1.
- Samples (A) and (C) were prepared according to the sample preparation methods (B) and (D).
- a colored guinea pig (Weiser Maples, 5 weeks old, male) with melanin-producing cells is shaved, and the shaved part is washed with lukewarm water, and the melanin dye is applied to an area of 1.5 cm X l. 5 cm. 30 mg of lyotropic liquid crystal compounded with 0.1% (weight ratio) of SOD (molecular weight 32000) having a production inhibitory effect was applied, and the effect on the epidermis was examined by the method described in Example 4.
- Fig. 9 shows a cross-sectional photograph of the skin (Fontanamasson staining).
- Fig. 9 shows a cross-sectional photograph of the skin (Fontanamasson staining).
- Fig. 9 shows a cross-sectional photograph of the skin (Fontanamasson staining).
- FIGS. 9 to 11 show a cross-sectional photograph of the skin (Fontanamasson staining) when 30 L of a dispersion in which SO D is dispersed in water at a rate of 0.1% (weight ratio) is applied.
- Fig. 11 shows a cross-sectional photograph of the skin when L is applied (Fontanamasson staining).
- the lyotropic liquid crystal containing SOD when the lyotropic liquid crystal containing SOD is applied, the amount of melanin pigment in the epidermis is larger than when applying a dispersion in which SOD is dispersed in water or only water. Remarkably reduced (judged by few black spots and areas). This was thought to be the force that SOD penetrated through the stratum corneum and reached the epidermis. Apply lyotropic liquid crystal containing SOD. It was considered that the thickening of the epidermis observed when applied was due to the skin regeneration promoting action of the lyotropic liquid crystal itself.
- Fig. 12 shows a cross-sectional photograph of the skin (Fontanamasson staining).
- arbutin which has an inhibitory effect on melanin pigment production
- thickening of the epidermis was observed, confirming that lyotropic liquid crystal itself has a skin regeneration promoting effect.
- FITC fluorescein with fluorescein isothiocyanate
- FIGS. 13 and 14 shows a fluorescence cross-sectional photograph of the skin when 30 L of a dispersion liquid in which oligo DNA fluorescently labeled with FITC is dispersed in water at a ratio (weight ratio) of 2% is applied.
- oligo DNA was mixed with lyotropic liquid crystal and applied, and penetrated into the epidermis 2 hours after application.
- Example 12 In the same manner as in Example 11, skin permeability was examined when lyotropic liquid crystal containing dextran (molecular weight 4000) fluorescently labeled with FITC at a ratio of 5% (weight ratio) was applied.
- Fig. 15 shows a fluorescence cross-sectional photograph of the skin. As is clear from FIG. 15, dextran penetrated into the epidermis after 15 minutes when it was formulated and applied to the lyophobic liquid crystal, and penetrated more into the interior over time.
- Example 11 the skin permeability when lyotropic liquid crystal containing dextran (molecular weight 70000) fluorescently labeled with FITC at a ratio (weight ratio) of 5% was applied was examined.
- skin permeability was examined when 30 L of a dispersion solution in which dextran (same as above) fluorescently labeled with FITC was dispersed in water at a ratio of 5% (weight ratio) was applied.
- Fig. 16 shows fluorescence cross-sectional photographs of each skin. As is clear from FIG. 16, dextran was mixed with lyotropic liquid crystal and applied, and after 15 minutes, it penetrated into the epidermis, and penetrated into the interior as time passed.
- lyotropic liquid crystal comprising a 860% by weight was prepared. By applying this lyotropic liquid crystal to the skin surface in advance and adding retinoic acid to the skin surface later, the transdermal absorbability of retinoic acid could be improved.
- a commercial antiseptic was added to the lyotropic liquid crystal of Example 14 to prepare a formulation.
- the lyotropic liquid crystal of Example 14 was blended with a self-prepared lotion base (milky lotion), and a commercially available antiseptic was added to prepare a lotion.
- the lotion base was prepared by mixing and emulsifying soy lecithin, cholesterol, PEG4000, cyclic silicone, carbopol (polymer gelling agent), ketrol (polymer gelling agent), and distilled water.
- the present invention is a lyotropic that has been used as a base material for externally used pharmaceuticals and cosmetics.
- the present invention has industrial applicability in that it can provide a transdermal absorption enhancer for use as a new medicinal liquid crystal.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Diabetes (AREA)
- Dispersion Chemistry (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Cosmetics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP06745834A EP1878425A4 (en) | 2005-04-28 | 2006-04-28 | TRANSDERMAL ABSORPTION ACCELERATOR |
US11/912,964 US20090075860A1 (en) | 2005-04-28 | 2006-04-28 | Transdermal absorption enhancer |
CA002607777A CA2607777A1 (en) | 2005-04-28 | 2006-04-28 | Transdermal absorption enhancer |
JP2007514833A JPWO2006118246A1 (ja) | 2005-04-28 | 2006-04-28 | 経皮吸収促進剤 |
KR1020077027691A KR101329907B1 (ko) | 2005-04-28 | 2006-04-28 | 경피 흡수 촉진제 |
US12/876,616 US9095560B2 (en) | 2005-04-28 | 2010-09-07 | Method of enhancing transdermal absorption using a composition comprising POE octyl dodecyl ether and squalane |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2005130962 | 2005-04-28 | ||
JP2005-130962 | 2005-04-28 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US11/912,964 A-371-Of-International US20090075860A1 (en) | 2005-04-28 | 2006-04-28 | Transdermal absorption enhancer |
US12/876,616 Continuation US9095560B2 (en) | 2005-04-28 | 2010-09-07 | Method of enhancing transdermal absorption using a composition comprising POE octyl dodecyl ether and squalane |
US12/876,616 Division US9095560B2 (en) | 2005-04-28 | 2010-09-07 | Method of enhancing transdermal absorption using a composition comprising POE octyl dodecyl ether and squalane |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2006118246A1 true WO2006118246A1 (ja) | 2006-11-09 |
Family
ID=37308040
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP2006/308975 WO2006118246A1 (ja) | 2005-04-28 | 2006-04-28 | 経皮吸収促進剤 |
Country Status (7)
Country | Link |
---|---|
US (2) | US20090075860A1 (ja) |
EP (1) | EP1878425A4 (ja) |
JP (1) | JPWO2006118246A1 (ja) |
KR (1) | KR101329907B1 (ja) |
CN (1) | CN101184475A (ja) |
CA (1) | CA2607777A1 (ja) |
WO (1) | WO2006118246A1 (ja) |
Cited By (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007308668A (ja) * | 2005-06-06 | 2007-11-29 | Konica Minolta Holdings Inc | 液晶組成物およびこれを用いた液晶表示素子 |
JP2009179570A (ja) * | 2008-01-29 | 2009-08-13 | Nano Egg:Kk | 皮膚外用組成物および色素沈着抑制剤 |
JP2010229117A (ja) * | 2009-03-30 | 2010-10-14 | Daiichi Sankyo Healthcare Co Ltd | 皮膚外用剤 |
WO2012137500A1 (ja) * | 2011-04-05 | 2012-10-11 | 株式会社ナノエッグ | メラニン色素排出用組成物 |
WO2014007266A1 (ja) * | 2012-07-02 | 2014-01-09 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
JPWO2012165468A1 (ja) * | 2011-05-31 | 2015-02-23 | 株式会社ナノエッグ | 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物 |
US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101184469B (zh) * | 2005-04-28 | 2011-08-24 | 独立行政法人科学技术振兴机构 | 皮肤再生促进剂 |
CN102076357A (zh) * | 2008-06-30 | 2011-05-25 | 久光制药株式会社 | 微针装置以及利用微针装置提高流感疫苗的功效性的方法 |
US20120160095A1 (en) * | 2010-11-29 | 2012-06-28 | The Regents Of The University Of Colorado, A Body Corporate | Novel Nanoporous Supported Lyotropic Liquid Crystal Polymer Membranes and Methods of Preparing and Using Same |
CN102038954B (zh) * | 2010-12-29 | 2012-05-09 | 济南市皮肤病防治院 | 一种适于制备维a酸水溶性制剂的水溶基质 |
US10195162B2 (en) * | 2011-12-27 | 2019-02-05 | Teikoku Seiyaku Co., Ltd. | Tolterodine-containing adhesive patch |
CN102526745B (zh) * | 2012-02-02 | 2013-02-27 | 西安交通大学 | 一种用微电场控制溶致液晶担载药物分子的缓释方法 |
EP3016655A4 (en) * | 2013-05-09 | 2017-04-12 | Zeenar Enterprises Pty Ltd | Niacin formulation |
CN104274337B (zh) * | 2013-07-02 | 2016-12-28 | 济南大学 | 一种生物液晶作为护肤品保湿成分及其制备方法 |
EP2823811A1 (en) * | 2013-07-09 | 2015-01-14 | OTC GmbH | Targeted active release system comprising solid lipid nano-particles |
DK3928763T3 (da) | 2015-03-02 | 2022-05-23 | Medlab Clinical U S Inc | Transmukosale og transdermale leveringssystemer |
US20180147138A1 (en) * | 2015-05-19 | 2018-05-31 | Medrx Co., Ltd | Transdermal liquid preparation |
WO2022152131A1 (zh) * | 2021-01-12 | 2022-07-21 | 广州新济药业科技有限公司 | 司美格鲁肽可溶性微针贴片及其制备方法 |
CN112972381B (zh) * | 2021-03-29 | 2022-02-01 | 华东理工大学 | 一种液晶包覆晶型药物的载药乳液及其制备方法 |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524958A (ja) * | 1997-04-17 | 2001-12-04 | ジーエス ディベロップメント アクティエボラーグ | 新規な液晶をベースとする生物接着性薬剤送出系 |
JP2004161739A (ja) * | 2002-09-25 | 2004-06-10 | Ltt Bio-Pharma Co Ltd | レチノイン酸ナノカプセル |
Family Cites Families (34)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
PH18145A (en) * | 1982-07-07 | 1985-04-03 | Unilever Nv | Hair conditioning preparation |
JPS6253910A (ja) * | 1985-09-02 | 1987-03-09 | Kao Corp | 液晶型油性化粧料 |
JPS6296585A (ja) * | 1985-10-24 | 1987-05-06 | Kao Corp | ラメラ型液晶構造体 |
JPH0661454B2 (ja) * | 1986-11-18 | 1994-08-17 | 株式会社資生堂 | マイクロエマルシヨン |
AU611421B2 (en) * | 1987-02-23 | 1991-06-13 | Shiseido Company Ltd. | Percutaneous absorption promoter and dermatologic preparation for external use |
JP3298867B2 (ja) * | 1988-06-20 | 2002-07-08 | 株式会社資生堂 | 透明組成物 |
JPH0374313A (ja) * | 1989-08-11 | 1991-03-28 | Kao Corp | 外用組成物 |
GB9207191D0 (en) * | 1992-04-01 | 1992-05-13 | Unilever Plc | Cosmetic compositions |
JPH0818950B2 (ja) * | 1992-05-01 | 1996-02-28 | 花王株式会社 | 化粧料 |
DE4238779A1 (de) * | 1992-11-12 | 1994-05-19 | Max Delbrueck Centrum | Lyotrophe Mesophasen und ihre Anwendung in der Pharmazie, der Kosmetik und der Dermatologie |
GB9312100D0 (en) | 1993-06-11 | 1993-07-28 | Procter & Gamble | Cosmetic make-up compositions |
US5688831A (en) * | 1993-06-11 | 1997-11-18 | The Procter & Gamble Company | Cosmetic make-up compositions |
DE4320119A1 (de) * | 1993-06-18 | 1994-12-22 | Henkel Kgaa | Flüssigkristalline wäßrige Tensidzubereitung |
JPH0899856A (ja) | 1994-09-29 | 1996-04-16 | Shiseido Co Ltd | 皮膚外用剤 |
US5871760A (en) * | 1994-11-28 | 1999-02-16 | The Procter & Gamble Company | Skin care compositions |
GB9423974D0 (en) * | 1994-11-28 | 1995-01-11 | Procter & Gamble | Skin care compositions |
GB9604674D0 (en) | 1996-03-05 | 1996-05-01 | Procter & Gamble | Skin care compositions |
WO2003106168A1 (en) * | 2000-08-16 | 2003-12-24 | Lyotropic Therapeutics, Inc. | Coated particles, methods of making and using |
JP3386989B2 (ja) * | 1997-11-10 | 2003-03-17 | 花王株式会社 | 化粧料 |
CA2322878C (en) * | 1998-03-16 | 2008-05-06 | Somerset Pharmaceuticals, Inc. | Use of selegiline or desmethylselegiline for treating wounds, burns and dermatological damage |
US6224888B1 (en) * | 1999-02-12 | 2001-05-01 | The Procter & Gamble Company | Cosmetic compositions |
JP4036560B2 (ja) * | 1999-02-23 | 2008-01-23 | 三菱鉛筆株式会社 | 液体化粧料 |
KR100320721B1 (ko) | 1999-07-24 | 2002-01-19 | 서경배 | 농도전이형 액정형성화합물 및 이의 제조방법 |
CN1240384C (zh) * | 1999-11-04 | 2006-02-08 | 美国爱科赛尔制药有限公司 | 石杉碱经皮给药制剂 |
US6238653B1 (en) * | 1999-12-22 | 2001-05-29 | Revlon Consumer Products Corporation | Liquid crystalline peroxide compositions and methods for coloring and/or bleaching hair |
KR100356676B1 (ko) | 2000-04-28 | 2002-10-18 | 주식회사 태평양 | 농도 전이형 액정형성화합물 및 이의 제조방법, 및 이를함유하는 화장료 조성물 |
JP2002053436A (ja) * | 2000-08-11 | 2002-02-19 | Lion Corp | 外用組成物 |
JP4880816B2 (ja) * | 2000-12-15 | 2012-02-22 | 株式会社ヤクルト本社 | 皮膚老化防止剤 |
JP2002348234A (ja) * | 2001-05-28 | 2002-12-04 | Purotekku:Kk | 薬物封入無機物微粒子、その製造法及び薬物封入無機物微粒子製剤 |
HUP0303313A2 (hu) * | 2003-10-09 | 2005-07-28 | Richter Gedeon Vegyészeti Gyár Rt. | Transzdermális gyógyszerkészítmények |
EP1674093A4 (en) * | 2003-10-15 | 2009-12-09 | Nanoegg Res Lab Inc | METHOD OF CHECKING THE PARTICLE SIZE OF RETINOLIC ACID NANOTEILS WITH A COATING OF POLYVALENT INORGANIC METAL SALT AND NANOTEHTES OBTAINED BY THE CONTROL PROCEDURE |
AU2003273010A1 (en) * | 2003-10-15 | 2005-05-05 | Ltt Bio-Pharma Co., Ltd. | Composition containing retinoic acid nanoparticles coated with polyvalent metal inorganic salt |
US20080274193A1 (en) * | 2004-01-23 | 2008-11-06 | Japan Science And Technology Agency | Retinoic Acid-Containing Antidiabetic Agent |
WO2006038721A1 (ja) * | 2004-10-07 | 2006-04-13 | Toyo Shinyaku Co., Ltd. | 外用剤 |
-
2006
- 2006-04-28 US US11/912,964 patent/US20090075860A1/en not_active Abandoned
- 2006-04-28 WO PCT/JP2006/308975 patent/WO2006118246A1/ja active Application Filing
- 2006-04-28 JP JP2007514833A patent/JPWO2006118246A1/ja active Pending
- 2006-04-28 KR KR1020077027691A patent/KR101329907B1/ko active IP Right Grant
- 2006-04-28 CA CA002607777A patent/CA2607777A1/en not_active Abandoned
- 2006-04-28 CN CNA2006800188368A patent/CN101184475A/zh active Pending
- 2006-04-28 EP EP06745834A patent/EP1878425A4/en not_active Withdrawn
-
2010
- 2010-09-07 US US12/876,616 patent/US9095560B2/en active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2001524958A (ja) * | 1997-04-17 | 2001-12-04 | ジーエス ディベロップメント アクティエボラーグ | 新規な液晶をベースとする生物接着性薬剤送出系 |
JP2004161739A (ja) * | 2002-09-25 | 2004-06-10 | Ltt Bio-Pharma Co Ltd | レチノイン酸ナノカプセル |
Non-Patent Citations (7)
Title |
---|
CSOKA I. ET AL.: "In vitro and in vivo percutaneous absorption of topical dosage forms: case studies", INT. J. PHARM., vol. 291, no. 1-2, 3 March 2005 (2005-03-03), pages 11 - 19, XP004737771 * |
GABBOUN N.H. ET AL.: "Release of salicyclic acid, diclofenac acid and diclofenac acid salts formisotropic and anisotropic nonionic surfactant systems across rat skin", INT. J. PHARM., vol. 212, 2001, pages 73 - 80, XP003006157 * |
MAKAI M. ET AL.: "Structural properties of nonionic surfactant/glycerol/paraddin lyotropic liquid crystals", COLLOID POLYM. SCI., vol. 281, 2003, pages 839 - 844, XP003006158 * |
NESSEEM D.I. ET AL.: "Formulation and evaluation of itraconazole via liquid crystal for topical delivery system", J. PHARM. BIOMED. ANAL., vol. 26, 2001, pages 387 - 399, XP003006159 * |
OSBORNE D.W. ET AL.: "Lyotropic Liquid Crystals as Topical Drug Delivery Vehicles", INT. J. PHARM. ADV., vol. 1, no. 1, 1995, pages 38 - 45, XP003006156 * |
See also references of EP1878425A4 * |
SUZUKI T.: "Ekisho de Keshohin o Tsukuru", CHEMISTRY & CHEMICAL INDUSTRY, vol. 51, no. 8, 1998, pages 1208 - 1211, XP003006160 * |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007308668A (ja) * | 2005-06-06 | 2007-11-29 | Konica Minolta Holdings Inc | 液晶組成物およびこれを用いた液晶表示素子 |
JP2009179570A (ja) * | 2008-01-29 | 2009-08-13 | Nano Egg:Kk | 皮膚外用組成物および色素沈着抑制剤 |
JP2010229117A (ja) * | 2009-03-30 | 2010-10-14 | Daiichi Sankyo Healthcare Co Ltd | 皮膚外用剤 |
WO2012137500A1 (ja) * | 2011-04-05 | 2012-10-11 | 株式会社ナノエッグ | メラニン色素排出用組成物 |
JPWO2012165468A1 (ja) * | 2011-05-31 | 2015-02-23 | 株式会社ナノエッグ | 親油性化合物を高濃度で含有する液晶組成物の製造方法及びその方法によって製造された液晶組成物 |
WO2014007266A1 (ja) * | 2012-07-02 | 2014-01-09 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
JPWO2014007266A1 (ja) * | 2012-07-02 | 2016-06-02 | 大日本住友製薬株式会社 | 癌抗原ペプチド経皮剤 |
US9663563B2 (en) | 2013-03-12 | 2017-05-30 | Sumitomo Dainippon Pharma Co., Ltd. | Aqueous liquid composition |
Also Published As
Publication number | Publication date |
---|---|
EP1878425A4 (en) | 2009-08-26 |
US9095560B2 (en) | 2015-08-04 |
KR101329907B1 (ko) | 2013-11-14 |
CA2607777A1 (en) | 2006-11-09 |
KR20080011302A (ko) | 2008-02-01 |
EP1878425A1 (en) | 2008-01-16 |
US20110081418A1 (en) | 2011-04-07 |
CN101184475A (zh) | 2008-05-21 |
US20090075860A1 (en) | 2009-03-19 |
JPWO2006118246A1 (ja) | 2008-12-18 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2006118246A1 (ja) | 経皮吸収促進剤 | |
JP5271538B2 (ja) | 皮膚再生促進剤 | |
KR100394770B1 (ko) | 토코페롤 유도체를 이용하여 나노유화입자를 안정화시키는방법 및 나노유화입자를 함유하는 피부 외용제 조성물 | |
CA2943179A1 (en) | Compositions and methods for enhancing the topical application of an acidic benefit agent | |
US8541010B2 (en) | Cosmetic composition comprising double-shell nano-structure | |
KR100810164B1 (ko) | 이데베논 나노캡슐을 함유하는 주름개선 화장료 조성물 및이의 제조방법 | |
KR20020079150A (ko) | 고분자 나노입자를 이용한 경피흡수제 및 이를 함유한외용제 조성물 | |
Gu et al. | Hair follicle-targeting drug delivery strategies for the management of hair follicle-associated disorders | |
KR100422763B1 (ko) | 경피흡수 촉진 능력이 우수한 식물성 나노입자의 제조 및이를 함유하는 화장료 및 의약용 외용제 조성물 | |
JP5137256B2 (ja) | 皮膚効果剤の増強された送達 | |
JP6959596B2 (ja) | 皮膚外用剤および皮膚バリア機能改善剤 | |
JP3834563B2 (ja) | アルブチンを利用した安定なナノ乳化粒子の製造方法及びナノ乳化粒子を含有する化粧料組成物 | |
KR20120114730A (ko) | 마이크로에멀젼에 의한 감마오리자놀을 함유한 경피약물전달 조성물 | |
KR100924643B1 (ko) | 아텔로콜라겐을 포집한 리포좀의 제조방법 | |
JP2014141479A (ja) | 有効成分の経皮吸収性の向上方法、及び化粧料 | |
KR20140117042A (ko) | 리포아미노산을 함유한 리파좀 캡슐 조성물, 그의 제조방법 및 그를 함유한 화장료 조성물 | |
EP4112044A1 (en) | Composition for particle-mediated transport of a dissolved active agent into hair follicles | |
KR100501309B1 (ko) | 알부틴 함유 나노유화 화장료 조성물의 제조방법 | |
KR20100036296A (ko) | 나노유화입자를 이용한 보조효소 함유 화장료 조성물 | |
KR101114909B1 (ko) | 피부친화성 폴리락타이드글리코라이드 나노입자의 제조방법 | |
KR20100111311A (ko) | 피부 외용 조성물 및 미백 화장료 | |
FR2949968A1 (fr) | Composition injectable comprenant une dispersion vesiculaire comprenant des ceramides et de l'acide hyaluronique, utilisation et procede | |
KR20040105169A (ko) | 알부틴을 이용하여 제조한 안정한 나노유화입자 및 이를함유한 화장료 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 200680018836.8 Country of ref document: CN |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2007514833 Country of ref document: JP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2607777 Country of ref document: CA Ref document number: 11912964 Country of ref document: US |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2006745834 Country of ref document: EP |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1020077027691 Country of ref document: KR |
|
WWP | Wipo information: published in national office |
Ref document number: 2006745834 Country of ref document: EP |